Company Overview and News

KLCI dips 0.24% in line with weaker regional markets

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI dipped 0.24% in line with tjhe weaker regional markets.
GMALY 7052 5183 4715 GMALF PECGF 2216

Limited impact seen from Indonesia moratorium

LOCAL planters with operations in Indonesia are not expected to be severely impacted by the latter’s recent decision to impose a three-year moratorium on new oil palm plantations, according to analysts.
KLKBY 2445 SMEBF 2216 4197 2291

IJM Plantations’ Malaysia FFB output seen to rise from October

2018-09-21 theedgemarkets
IJM Plantations Bhd (Sept 20, RM2.50) Maintain buy with an unchanged fair value (FV) of RM3: Our FV is based on a 15% discount to IJM Plantations Bhd’s revalued net asset valuation (RNAV) of RM3.53/share. Our FV of RM3/share implies a financial year 2020 forward (FY20F) price-earnings ratio (PER) of 25.2 times. We have used RNAV instead of PER to value IJM Plantations as we believe that IJM Plantations is a takeover target.

Demand for CPO expected to pick up towards 4Q of 2018

2018-09-14 theedgemarkets
Plantation sector Maintain neutral: Malaysia’s crude palm oil (CPO) production increased for a second straight month in August, rising by 7.9% month-on-month (m-o-m) to 1.62 million tonnes. The fresh fruit bunch (FFB) yield also improved across Peninsular Malaysia, Sabah and Sarawak, rising by 8.7%, 3.2% and 12.6% year-on-year (y-o-y) respectively to 1.38 tonnes/ha, 1.28 tonnes/ha and 1.52 tonnes/ha.
KLKBY 2445 5138 2216 4383 2291 4243 5012

KLCI remains in the red, down 0.52% in line with region

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI remained in the red at mid-morning and was down 0.52%, in line with the weaker regional markets.
HLFBF APEXF 7173 PBLOF 7090 4065 7036 1082 BATS 4162 0162 1295 8311 6033 PNADF 0104 2216 5819 PNAGF 3719

IJM Corp sees lower FY19 order book replenishment

2018-08-29 theedgemarkets
KUALA LUMPUR: Builder and property developer IJM Corp Bhd expects a lower order book replenishment in the current financial year ending March 31, 2019 (FY19) as it already secured some of the jobs in FY18.
KLKBY 2445 5138 2216

IJM Corp remains committed to plantation unit amid speculation of possible disposal

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): IJM Corp Bhd today described as “mere speculation” news reports that the group has received offers to acquire its 56% stake in IJM Plantations Bhd.
KLKBY 2445 5138 2216

Bursa Malaysia stays higher at mid-morning

2018-08-07 malaymail
KUALA LUMPUR, Aug 7 ― Persistent buying interest in selected heavyweights, especially in trade and services counters, lifted Bursa Malaysia to remain higher at mid-morning today.
PNADF PBLOF 5225 2216 7036 Q0F 1295 BSMAF IHHHF PNAGF 6033 1818

KLCI gains 0.39%, tracks regional markets

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.39% at mid-morning today, lifted by index-linked blue chips and tracking the steady regional markets.
7052 7036 5681 BATS 4162 3034 1481 5014 6033 0152 1783 PNADF 5225 SGPBY 5209 2216 2739 MYPRY Q0F IHHHF PNAGF

IJM Plantations up 9.78% after reported as takeover target

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): IJM Plantations Bhd gained as much as 22 sen or 9.78% to a six-month high of RM2.47 in early trade today after a news report cited the company as a takeover target.
5138 2216

IJM Plantations shares rise on talk of takeover

KUALA LUMPUR: Shares in IJM Plantations Bhd jumped almost 10% in early trade Tuesday after following a news report that the company could to be a takeover target.
2216 BSMAF 1818

Trading ideas: PRG, KKB, Axis REIT, Only World, IJM Plantations

KUALA LUMPUR: JF Apex Research expects PRG Holdings Bhd , KKB Engineering Bhd , Axis Real Estate Investment Trust (Axis REIT), Only World Group Holdings Bhd and IJM Plantations Bhd to generate trading interest following their latest news.
5106 5260 2216 7168 9466

IJM Plantations a target, cash-rich IOI leading suitor

High demand: Among the suitors eyeing IJM Plantations, which has 61,000ha of planted area in Sabah, Kalimantan and Sumatra, are plantation groups such as IOI and Hap Seng Plantations.
5138 1996 2216 5254

RAM sees full-year CPO prices near RM2,300/tonne

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): Crude palm oil (CPO) prices are expected to average at the lower end of the RM2,300 to RM2,500 per tonne range this year, according to RAM Rating Services Sdn Bhd.
KLKBY 2445 2216 UPBMF 2089

Research house says CPO production may go up

THINGS are not looking great for Malaysian plantation players, with rising cost and no strong catalysts to boost crude palm oil (CPO) prices.
KLKBY 2445 5126 SARKF 2216 4065 2291 5112

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...